Lower Prevalence of Osteoporosis in Patients with COPD Taking Anti-Inflammatory Compounds for the Treatment of Diabetes: Results from COSYCONET

References

• Franco CB, Paz-Filho G, Gomes PE, et al. Chronic obstructive pulmonary disease is associated with osteoporosis and low levels of vitamin D. Osteoporos Int. 2009;20(11):1881–1887. doi:10.1007/s00198-009-0890-5
   PubMed Web of Science ®Google Scholar
• Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):728–735. doi:10.1164/rccm.201209-1665OC
   PubMed Web of Science ®Google Scholar
• Sarkar M, Bhardwaj R, Madabhavi I, Khatana J. Osteoporosis in chronic obstructive pulmonary disease. Clin Med Insights Circ Respir Pulm Med. 2015;9:5–21. doi:10.4137/CCRPM.S22803
   PubMed Web of Science ®Google Scholar
• Karch A, Vogelmeier C, Welte T, et al. The German COPD cohort COSYCONET: aims, methods and descriptive analysis of the study population at baseline. Respir Med. 2016;114:27–37. doi:10.1016/j.rmed.2016.03.008
   PubMed Web of Science ®Google Scholar
• Okazaki R, Watanabe R, Inoue D. Osteoporosis associated with chronic obstructive pulmonary disease. J Bone Metab. 2016;23(3):111–120. doi:10.11005/jbm.2016.23.3.111
   PubMedGoogle Scholar
• Nayyar N, Sood RG, Sarkar M, Tomar A, Thakur V, Bhoil R. Prevalence of osteoporosis and osteopenia in stable patients of chronic obstructive pulmonary disease in Sub-Himalayan region of Himachal Pradesh, India. J Family Med Prim Care. 2017;6(3):595–599. doi:10.4103/2249-4863.222013
   PubMedGoogle Scholar
• Liao KM, Chiu KL, Chen CY. Prescription patterns in patients with chronic obstructive pulmonary disease and osteoporosis. Int J Chron Obstruct Pulmon Dis. 2021;16:761–769. doi:10.2147/COPD.S289799
   PubMed Web of Science ®Google Scholar
• Inoue D, Watanabe R, Okazaki R. COPD and osteoporosis: links, risks, and treatment challenges. Int J Chron Obstruct Pulmon Dis. 2016;11:637–648. doi:10.2147/COPD.S79638
   PubMed Web of Science ®Google Scholar
• Bikov A, Horvath A, Tomisa G, Bartfai L, Bartfai Z. Changes in the burden of comorbidities in patients with COPD and asthma-COPD overlap according to the GOLD 2017 recommendations. Lung. 2018;196(5):591–599. doi:10.1007/s00408-018-0141-7
   PubMed Web of Science ®Google Scholar
• Liang B, Feng Y. The association of low bone mineral density with systemic inflammation in clinically stable COPD. Endocrine. 2012;42(1):190–195. doi:10.1007/s12020-011-9583-x
   PubMed Web of Science ®Google Scholar
• Kahnert K, Lucke T, Biertz F, et al. Transfer factor for carbon monoxide in patients with COPD and diabetes: results from the German COSYCONET cohort. Respir Res. 2017;18(1):14. doi:10.1186/s12931-016-0499-0
   PubMedGoogle Scholar
• Tsalamandris S, Antonopoulos AS, Oikonomou E, et al. The role of inflammation in diabetes: current concepts and future perspectives. Eur Cardiol. 2019;14(1):50–59. doi:10.15420/ecr.2018.33.1
   PubMed Web of Science ®Google Scholar
• Aung M, Amin S, Gulraiz A, Gandhi FR, Pena Escobar JA, Malik BH. The future of metformin in the prevention of diabetes-related osteoporosis. Cureus. 2020;12(9):e10412.
   PubMed Web of Science ®Google Scholar
• Kalaitzidis RG, Sarafidis PA, Bakris GL. Effects of thiazolidinediones beyond glycaemic control. Curr Pharm Des. 2009;15(5):529–536. doi:10.2174/138161209787315693
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Esser N, Paquot N. Antidiabetic agents: potential anti-inflammatory activity beyond glucose control. Diabetes Metab. 2015;41(3):183–194. doi:10.1016/j.diabet.2015.02.003
   PubMed Web of Science ®Google Scholar
• Cortet B, Lucas S, Legroux-Gerot I, Penel G, Chauveau C, Paccou J. Bone disorders associated with diabetes mellitus and its treatments. Joint Bone Spine. 2019;86(3):315–320. doi:10.1016/j.jbspin.2018.08.002
   PubMed Web of Science ®Google Scholar
• Lutter JI, Jorres RA, Trudzinski FC, et al. Treatment of COPD groups GOLD A and B with inhaled corticosteroids in the COSYCONET cohort - determinants and consequences. Int J Chron Obstruct Pulmon Dis. 2021;16:987–998. doi:10.2147/COPD.S304532
   PubMed Web of Science ®Google Scholar
• Graf J, Jorres RA, Lucke T, Nowak D, Vogelmeier CF, Ficker JH. Medical treatment of COPD. Dtsch Arztebl Int. 2018;155(37):599–605.
   PubMedGoogle Scholar
• Compston J. Glucocorticoid-induced osteoporosis: an update. Endocrine. 2018;61(1):7–16. doi:10.1007/s12020-018-1588-2
   PubMed Web of Science ®Google Scholar
• Kumarathas I, Harslof T, Andersen CU, et al. The risk of osteoporosis in patients with asthma. Eur Clin Respir J. 2020;7(1):1763612. doi:10.1080/20018525.2020.1763612
   PubMed Web of Science ®Google Scholar
• Cortizo AM, Sedlinsky C, McCarthy AD, Blanco A, Schurman L. Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture. Eur J Pharmacol. 2006;536(1–2):38–46. doi:10.1016/j.ejphar.2006.02.030
   PubMed Web of Science ®Google Scholar
• Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Sugimoto T. Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. Biochem Biophys Res Commun. 2008;375(3):414–419. doi:10.1016/j.bbrc.2008.08.034
   PubMed Web of Science ®Google Scholar
• Gao Y, Li Y, Xue J, Jia Y, Hu J. Effect of the anti-diabetic drug metformin on bone mass in ovariectomized rats. Eur J Pharmacol. 2010;635(1–3):231–236. doi:10.1016/j.ejphar.2010.02.051
   PubMed Web of Science ®Google Scholar
• Stunes AK, Erben RG, Schuler C, et al. Skeletal effects of plyometric exercise and metformin in ovariectomized rats. Bone. 2020;132:115193. doi:10.1016/j.bone.2019.115193
   PubMed Web of Science ®Google Scholar
• Zhao J, Li Y, Zhang H, et al. Preventative effects of metformin on glucocorticoid-induced osteoporosis in rats. J Bone Miner Metab. 2019;37(5):805–814. doi:10.1007/s00774-019-00989-y
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Eur Respir J. 2017;49(3):1700214. doi:10.1183/13993003.00214-2017
   PubMed Web of Science ®Google Scholar
• Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324–1343. doi:10.1183/09031936.00080312
   PubMed Web of Science ®Google Scholar
• Singh D, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164. doi:10.1183/13993003.00164-2019
   PubMed Web of Science ®Google Scholar
• Lucke T, Herrera R, Wacker M, et al. Systematic analysis of self-reported comorbidities in large cohort studies - a novel stepwise approach by evaluation of medication. PLoS One. 2016;11(10):e0163408. doi:10.1371/journal.pone.0163408
   PubMed Web of Science ®Google Scholar
• Kellerer C, Kahnert K, Trudzinski FC, et al. COPD maintenance medication is linked to left atrial size: results from the COSYCONET cohort. Respir Med. 2021;185:106461.
   PubMed Web of Science ®Google Scholar
• Chen YW, Ramsook AH, Coxson HO, Bon J, Reid WD. Prevalence and risk factors for osteoporosis in individuals with COPD: a systematic review and meta-analysis. Chest. 2019;156(6):1092–1110. doi:10.1016/j.chest.2019.06.036
   PubMed Web of Science ®Google Scholar
• De Laet C, Kanis JA, Oden A, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int. 2005;16(11):1330–1338. doi:10.1007/s00198-005-1863-y
   PubMed Web of Science ®Google Scholar
• Xiang BY, Huang W, Zhou GQ, Hu N, Chen H, Chen C. Body mass index and the risk of low bone mass-related fractures in women compared with men: a PRISMA-compliant meta-analysis of prospective cohort studies. Medicine. 2017;96(12):e5290. doi:10.1097/MD.0000000000005290
   PubMed Web of Science ®Google Scholar
• Hariri AF, Almatrafi MN, Zamka AB, et al. Relationship between body mass index and T-scores of bone mineral density in the hip and spine regions among older adults with diabetes: a retrospective review. J Obes. 2019;2019:9827403. doi:10.1155/2019/9827403
   PubMed Web of Science ®Google Scholar
• Xuan R, Song Y, Baker JS, Gu Y. The evaluation of bone mineral density based on age and anthropometric parameters in Southeast Chinese adults: a cross-sectional study. Med Sci Monit. 2020;26:e923603. doi:10.12659/MSM.923603
   PubMed Web of Science ®Google Scholar
• Bon J, Nouraie SM, Smith KJ, et al. Lung-specific risk factors associated with incident hip fracture in current and former smokers. J Bone Miner Res. 2020;35(10):1952–1961. doi:10.1002/jbmr.4103
   PubMed Web of Science ®Google Scholar
• Lu PC, Yang YH, Guo SE, Yang TM. Factors associated with osteoporosis in patients with chronic obstructive pulmonary disease-a nationwide retrospective study. Osteoporos Int. 2017;28(1):359–367. doi:10.1007/s00198-016-3732-2
   PubMed Web of Science ®Google Scholar
• Chiu KL, Lee CC, Chen CY. Evaluating the association of osteoporosis with inhaled corticosteroid use in chronic obstructive pulmonary disease in Taiwan. Sci Rep. 2021;11(1):724. doi:10.1038/s41598-020-80815-y
   PubMed Web of Science ®Google Scholar
• den Uyl D, Nurmohamed MT, van Tuyl LH, Raterman HG, Lems WF. (Sub)clinical cardiovascular disease is associated with increased bone loss and fracture risk; a systematic review of the association between cardiovascular disease and osteoporosis. Arthritis Res Ther. 2011;13(1):R5. doi:10.1186/ar3224
   PubMed Web of Science ®Google Scholar
• Leidig-Bruckner G, Grobholz S, Bruckner T, Scheidt-Nave C, Nawroth P, Schneider JG. Prevalence and determinants of osteoporosis in patients with type 1 and type 2 diabetes mellitus. BMC Endocr Disord. 2014;14:33. doi:10.1186/1472-6823-14-33
   PubMed Web of Science ®Google Scholar
• Kelsey JL. Risk factors for osteoporosis and associated fractures. Public Health Rep. 1989;104 Suppl(Suppl):14–20.
   PubMedGoogle Scholar
• Rejnmark L, Mosekilde L, Andreasen F. [Diuretics and osteoporosis]. Nord Med. 1998;113(2):53–59. Danish.
   PubMedGoogle Scholar
• Miller J, Edwards LD, Agusti A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013;107(9):1376–1384. doi:10.1016/j.rmed.2013.05.001
   PubMed Web of Science ®Google Scholar
• Pollack RM, Donath MY, LeRoith D, Leibowitz G. Anti-inflammatory agents in the treatment of diabetes and its vascular complications. Diabetes Care. 2016;39(Suppl 2):S244–S252. doi:10.2337/dcS15-3015
   PubMedGoogle Scholar
• Yaribeygi H, Atkin SL, Pirro M, Sahebkar A. A review of the anti-inflammatory properties of antidiabetic agents providing protective effects against vascular complications in diabetes. J Cell Physiol. 2019;234(6):8286–8294. doi:10.1002/jcp.27699
   PubMed Web of Science ®Google Scholar
• Lu CH, Chung CH, Kuo FC, et al. Metformin attenuates osteoporosis in diabetic patients with carcinoma in situ: a nationwide, retrospective, matched-cohort study in Taiwan. J Clin Med. 2020;9(9):2839. doi:10.3390/jcm9092839
   PubMed Web of Science ®Google Scholar
• Tseng CH. Metformin use is associated with a lower risk of osteoporosis/vertebral fracture in Taiwanese patients with type 2 diabetes mellitus. Eur J Endocrinol. 2021;184(2):299–310. doi:10.1530/EJE-20-0507
   PubMed Web of Science ®Google Scholar
• Blumel JE, Arteaga E, Aedo S, et al. Metformin use is associated with a lower risk of osteoporosis in adult women independent of type 2 diabetes mellitus and obesity. REDLINC IX study. Gynecol Endocrinol. 2020;36(5):421–425. doi:10.1080/09513590.2020.1718092
   PubMed Web of Science ®Google Scholar
• McCarthy AD, Cortizo AM, Sedlinsky C. Metformin revisited: does this regulator of AMP-activated protein kinase secondarily affect bone metabolism and prevent diabetic osteopathy. World J Diabetes. 2016;7(6):122–133. doi:10.4239/wjd.v7.i6.122
   PubMedGoogle Scholar
• Chau DL, Edelman SV, Chandran M. Osteoporosis and diabetes. Curr Diab Rep. 2003;3(1):37–42. doi:10.1007/s11892-003-0051-8
   PubMedGoogle Scholar
• Carnevale V, Romagnoli E, D’Erasmo E. Skeletal involvement in patients with diabetes mellitus. Diabetes Metab Res Rev. 2004;20(3):196–204. doi:10.1002/dmrr.449
   PubMed Web of Science ®Google Scholar
• Mai QG, Zhang ZM, Xu S, et al. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. J Cell Biochem. 2011;112(10):2902–2909. doi:10.1002/jcb.23206
   PubMed Web of Science ®Google Scholar
• Mu W, Wang Z, Ma C, et al. Metformin promotes the proliferation and differentiation of murine preosteoblast by regulating the expression of sirt6 and oct4. Pharmacol Res. 2018;129:462–474. doi:10.1016/j.phrs.2017.11.020
   PubMed Web of Science ®Google Scholar
• Leech JA, Dulberg C, Kellie S, Pattee L, Gay J. Relationship of lung function to severity of osteoporosis in women. Am Rev Respir Dis. 1990;141(1):68–71. doi:10.1164/ajrccm/141.1.68
   PubMed Web of Science ®Google Scholar
• Alter P, Orszag J, Kellerer C, et al. Prediction of air trapping or pulmonary hyperinflation by forced spirometry in COPD patients: results from COSYCONET. ERJ Open Res. 2020;6(3):00092–2020. doi:10.1183/23120541.00092-2020
   PubMedGoogle Scholar
• Park HJ, Cho JH, Kim HJ, Park JY, Lee HS, Byun MK. The effect of low body mass index on the development of chronic obstructive pulmonary disease and mortality. J Intern Med. 2019;286(5):573–582. doi:10.1111/joim.12949
   PubMed Web of Science ®Google Scholar
• Ohara T, Hirai T, Muro S, et al. Relationship between pulmonary emphysema and osteoporosis assessed by CT in patients with COPD. Chest. 2008;134(6):1244–1249. doi:10.1378/chest.07-3054
   PubMed Web of Science ®Google Scholar
• Konigsdorfer N, Jorres RA, Sohler S, et al. Adherence to respiratory and nonrespiratory medication in patients with COPD: results of the German COSYCONET cohort. Patient Prefer Adherence. 2019;13:1711–1721.
   PubMed Web of Science ®Google Scholar